High Response Rates to CAR-T Seen in Mantle Cell Lymphoma
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.
Brain Cancer
BRAIN CANCER ADVISOR
FEATURED CONTENT
-
-
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic. -
Time to Radiotherapy After Glioblastoma Resection Affects Survival Outcomes
A large retrospective analysis demonstrated that a delay of 4 to 8 weeks for adjuvant radiotherapy following surgical resection of glioblastoma improved survival. -
CAR-T in ALL: Records Reveal Direct Costs for Hospitalization Approach $300K
The median total cost of hospitalization resulting from CAR-T treatment was found to be $380,052, with a median direct cost of $262,981. -
Is Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma Beneficial?
Neoadjuvant chemotherapy was found to negatively impact survival in resectable malignant pleural mesothelioma.
BRAIN CANCER NEWS
Peptide Derived From Scorpion Venom Helps CAR-T Cells Kill Gliomas in Preclinical Tests
Harnessing Key Elements of the Ebola Virus in Animal Models of Glioblastoma
Maximal Resection of Glioblastomas May Up Survival
Bevacizumab Adoption Tied to Use by Peers
One-Third of Glioblastomas Had Molecular Changes at Recurrence
Want to read more?
Please login or register first to view this content.
Next post in Brain Cancer
